Genomic epidemiology and transmission dynamics of recurrent Clostridioides difficile infection in Western Australia

[1]  S. Marcella,et al.  Linkage study of surveillance and hospital admission data to investigate Clostridium difficile infection in hospital patients in Perth, Western Australia. , 2022, Anaerobe.

[2]  E. Kuijper,et al.  European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. , 2021, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[3]  T. Riley,et al.  A species-wide genetic atlas of antimicrobial resistance in Clostridioides difficile , 2021, bioRxiv.

[4]  Monica Lahra,et al.  Antimicrobial resistance surveillance of Clostridioides difficile in Australia, 2015-18. , 2021, The Journal of antimicrobial chemotherapy.

[5]  Monica Lahra,et al.  Laboratory-Based Surveillance of Clostridium difficile Infection in Australian Health Care and Community Settings, 2013 to 2018 , 2020, Journal of Clinical Microbiology.

[6]  T. Riley,et al.  Clostridium difficile and One Health. , 2020, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[7]  E. Bouza,et al.  Analysis of C. difficile infection–related outcomes in European participants in the bezlotoxumab MODIFY I and II trials , 2020, European Journal of Clinical Microbiology & Infectious Diseases.

[8]  D. Gerding,et al.  Trends in U.S. Burden of Clostridioides difficile Infection and Outcomes. , 2020, The New England journal of medicine.

[9]  Robin Patel,et al.  Clostridioides difficile Whole Genome Sequencing Differentiates Relapse with the Same Strain from Reinfection with a New Strain. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  B. Guery,et al.  Clostridioides difficile: diagnosis and treatments , 2019, BMJ.

[11]  P. Tsai,et al.  Evolutionary and Genomic Insights into Clostridioides difficile Sequence Type 11: a Diverse Zoonotic and Antimicrobial-Resistant Lineage of Global One Health Importance , 2019, mBio.

[12]  T. Riley,et al.  Recurrence of Clostridium difficile infection in the Western Australian population , 2019, Epidemiology and Infection.

[13]  R. Leong,et al.  A series of three cases of severe Clostridium difficile infection in Australia associated with a binary toxin producing clade 2 ribotype 251 strain. , 2019, Anaerobe.

[14]  T. Riley,et al.  Antimicrobial susceptibility of Clostridium difficile isolated from food and environmental sources in Western Australia. , 2018, International journal of antimicrobial agents.

[15]  M. Delmée,et al.  Two Distinct Patterns of Clostridium difficile Diversity Across Europe Indicating Contrasting Routes of Spread , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  T. Riley,et al.  High prevalence of Clostridium difficile on retail root vegetables, Western Australia , 2018, Journal of applied microbiology.

[17]  S. Tschudin-Sutter,et al.  Distinguishing Clostridium difficile Recurrence From Reinfection: Independent Validation of Current Recommendations , 2017, Infection Control & Hospital Epidemiology.

[18]  T. Peto,et al.  Comparison of Control of Clostridium difficile Infection in Six English Hospitals Using Whole-Genome Sequencing , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  T. Riley,et al.  High prevalence of toxigenic Clostridium difficile in public space lawns in Western Australia , 2017, Scientific Reports.

[20]  A. Ananthakrishnan,et al.  A Comprehensive Study of Costs Associated With Recurrent Clostridium difficile Infection , 2016, Infection Control & Hospital Epidemiology.

[21]  A. Galvani,et al.  Quantifying Transmission of Clostridium difficile within and outside Healthcare Settings , 2016, Emerging infectious diseases.

[22]  Jason C. Gallagher,et al.  Clinical and Economic Benefits of Fidaxomicin Compared to Vancomycin for Clostridium difficile Infection , 2015, Antimicrobial Agents and Chemotherapy.

[23]  T. Rogers,et al.  Whole-genome sequencing improves discrimination of relapse from reinfection and identifies transmission events among patients with recurrent Clostridium difficile infections. , 2015, The Journal of hospital infection.

[24]  D. Gerding,et al.  Molecular Epidemiology of Clostridium difficile Infections in Children: A Retrospective Cohort Study , 2015, Infection Control & Hospital Epidemiology.

[25]  T. Riley,et al.  Nationwide Surveillance Study of Clostridium difficile in Australian Neonatal Pigs Shows High Prevalence and Heterogeneity of PCR Ribotypes , 2014, Applied and Environmental Microbiology.

[26]  T. Peto,et al.  Whole-Genome Sequencing Demonstrates That Fidaxomicin Is Superior to Vancomycin for Preventing Reinfection and Relapse of Infection With Clostridium difficile , 2013, The Journal of infectious diseases.

[27]  Daniel J. Wilson,et al.  Microevolutionary analysis of Clostridium difficile genomes to investigate transmission , 2012, Genome Biology.

[28]  Jane W. Marsh,et al.  Association of Relapse of Clostridium difficile Disease with BI/NAP1/027 , 2012, Journal of Clinical Microbiology.

[29]  K. Sepkowitz,et al.  Hospital-Onset Clostridium difficile Infection Rates in Persons with Cancer or Hematopoietic Stem Cell Transplant: A C3IC Network Report , 2012, Infection Control & Hospital Epidemiology.

[30]  N. E. Babady,et al.  Relapse versus reinfection: surveillance of Clostridium difficile infection. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  Stuart Johnson.  Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. , 2009, The Journal of infection.

[32]  K. Garey,et al.  Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. , 2008, The Journal of hospital infection.

[33]  S. Routhier,et al.  Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  Lynne V McFarland,et al.  Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease , 2002, American Journal of Gastroenterology.

[35]  Nader Pourmand,et al.  Determining the cause of recurrent Clostridium difficile infection using whole genome sequencing. , 2017, Diagnostic microbiology and infectious disease.

[36]  Matthew Sims,et al.  Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection. , 2017 .

[37]  C. Kelly.  Can we identify patients at high risk of recurrent Clostridium difficile infection? , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[38]  M. Ferraro.  Performance standards for antimicrobial susceptibility testing , 2001 .